Abstract
Sepsis is a systemic infection mainly caused by bacterial infections. Despite all efforts and advances in treatment of sepsis, it's still considered as one of the leading causes of death in the hospitalized patients. Today we have to use novel therapies and one of the most important is cell free therapy. Exosomes have been introduced to have all cell contents without compatible tissue complex proteins which is a good candidate for transplantation. Unrestricted somatic stem cells (USSC) also known as mesenchymal stem cell progenitors due to their high proliferative capacity and low immune response, which is a novel therapy for sepsis.
In this study, the effect of USSC-derived exosomes on sepsis was investigated using a mouse model. USSCs were isolated from human cord blood and characterized by flow cytometry and multilineage differentiation. The exosomes were then harvested from USSCs and characterized by transmission electron microscopy, Western blotting, and dynamic light scattering. The harvested exosomes were injected into the mouse model of sepsis. Biochemical, histological, molecular, and survival studies were performed in different groups.
Our observation showed that USSC-derived exosomes can reduce inflammation in septic mice. Histopathological and biochemical findings in the sham group obviously showed multiorgan involvement, but these changes disappeared after seven days of exosome administration. Moreover, the expression of IRAK-1 and TRAF-6 (main adapter molecules in signaling pathways of inflammation) was decreased through negative regulation by miR-146a after 72 h of exosome administration; finally, it leads to a 2-fold increase in the level of IL-10 and a 2-fold decrease in the levels of IL-6 and TNF-α . In conclusion, we reported that direct injection of USSC- derived exosomes can be one of the important methods for the treatment of various aspects of sepsis due to their immunomodulatory properties.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献